Solubility

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
星期一, 五月 6, 2024
Net, Skin, Investment, Solubility, Research, Diabetes, BioCryst Pharmaceuticals, Plasma, Injection, Webcast, Kallikrein, Prescription, Disease, Dehydration, Patient, Eye, Operating cost, Physician, Paratriathlon, EPS, Workforce, Infection, DME, Clinical trial, HAE, Diabetic retinopathy, Edema, Genetic disorder, GAAP, Netherton syndrome, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • These two successes helped us exceed our revenue projections for the quarter and, as a result, we are increasing our revenue guidance for 2024,” said Charlie Gayer, chief commercial officer of BioCryst.
  • Interest expense was $24.5 million in the first quarter of 2024, compared to $27.4 million in the first quarter of 2023 (-10.6 percent y-o-y).
  • Our references to our first quarter 2024 “non-GAAP pro forma” financial measures of adjusted net loss and adjusted earnings per share constitute non-GAAP financial measures.
  • ET today to discuss the financial results and provide a corporate update.

FITAID of LIFEAID Beverage Co. LLC, Releases Two New Flavors of FITAID RX Zero, Only One Will Stay

Retrieved on: 
星期三, 五月 8, 2024
Life Time Fitness, Solubility, Sports nutrition, Partnership, Guilt, Snow, TIME, Blue Raspberry, Apple, Creatine, Soft drink

SANTA CRUZ, Calif., May 7, 2024 /PRNewswire/ -- Fresh off the revamped formula release of their patented creatine infused ready to drink recovery beverage, FITAID delivers a unique product drop strategy, putting customers in control of their permanent flavor collection. With the record breaking introduction of their successful innovative partnership with supplement pioneer Glanbia® Nutritionals in March 2024, the entire FITAID RX line is now boosted with Encapsulated Creatine by Glanbia® Nutritionals's CreaBev®. After increasing solubility and stability within every can, the natural progression was to expand the flavor portfolio. The two new and naturally flavored options for their fitness enthusiasts are Blue Raspberry and Juicy Apple.

Key Points: 
  • The two new and naturally flavored options for their fitness enthusiasts are Blue Raspberry and Juicy Apple.
  • "Simply uncompromising" is how FITAID company President and Co-founder Aaron Hinde describes the latest innovation of FITAID RX Zero.
  • FITAID RX Zero Blue Raspberry and Juicy Apple are now available for purchase online and at select fitness retailers.
  • "We are kickstarting beverage season with an epic battle between our best flavors yet, and things are about to really heat up."

Mikart and Nano PharmaSolutions complete key milestones

Retrieved on: 
星期二, 五月 7, 2024
Nanotechnology, Solubility, Partnership, API, NPS, GMP

ATLANTA, May 7, 2024 /PRNewswire/ -- Mikart, LLC ("Mikart"), a leading contract development and manufacturing organization, is thrilled to announce a significant milestone in its collaboration with Nano PharmaSolutions, Inc. ("NPS").

Key Points: 
  • ATLANTA, May 7, 2024 /PRNewswire/ -- Mikart, LLC ("Mikart"), a leading contract development and manufacturing organization, is thrilled to announce a significant milestone in its collaboration with Nano PharmaSolutions, Inc. ("NPS").
  • Mikart and NPS entered into a groundbreaking collaboration agreement aimed at revolutionizing pharmaceutical development through NPS's innovative NanoTransformer™ technology, designed to enhance the solubility of pharmaceutical active ingredients (API).
  • At this stage of the relationship Mikart and NPS are now prepared to install the NanoTransformer™ capability at its Atlanta facility.
  • Kay Olmstead, PhD/MBA, Chief Executive Officer at NPS, added, "Nano PharmaSolutions is excited for this milestone which will provide the market with GMP manufacturing capabilities for the clinical development of nanomedicines, using our NanoTransformer™ technology at Mikart's facility."

MD Logic Health® Introduces Their New Low Molecular Bioactive Colostrum

Retrieved on: 
星期二, 四月 30, 2024
Sale, Digestion, Protein, Solubility, Pinnacle, Milk, Cytokine, MD, Logic, Probiotic, Peptide, Colostrum, Immunity, Absorption, Nutritional science, Fats, Dairy

MIAMI, April 30, 2024 /PRNewswire-PRWeb/ -- In an era where gut health is paramount, MD Logic Health® has once again raised the bar with the introduction of its Low Molecular Bioactive Colostrum), a new pinnacle in health supplements for superior gut health and overall well-being. Known for their unwavering dedication to excellence and innovation, MD Logic Health®'s latest formulation offers unparalleled potency, purity, and efficacy.

Key Points: 
  • MD Logic Health® raises the bar in gut health innovation with its new Low Molecular Bioactive Colostrum, offering unmatched potency and efficacy.
  • - Wesley Ramjeet, CEO of MD Logic Health®
    As the market's demand for effective gut health solutions intensifies, MD Logic Health® delivers a compelling answer with its Low Molecular Bioactive Colostrum.
  • The Low Molecular Bioactive Colostrum is sourced from all-natural, hormone-free grass-fed cattle maintained on a carefully selected, nutrient-rich diet.
  • MD Logic Health®'s Low Molecular Bioactive Colostrum is a revolution in wellness, designed to meet the needs of modern health-conscious consumers.

DolCas Biotech demonstrates Curcugen® in chocolate at Vitafoods

Retrieved on: 
星期二, 四月 30, 2024
Capsule, Solubility, Polysaccharide, Health, Tablet, Food, Curcumin, Medicine, DMC, Drink, Absorption, Plasma

LANDING, N.J., April 30, 2024 /PRNewswire/ -- DolCas Biotech, LLC will introduce a new prototype of delicious chocolate laced with its flagship curcumin ingredient Curcugen® to demonstrate its versatility in functional foods and beverages. The tasty reveal will occur at the Vitafoods Europe in Geneva, booth #N217, May 14-16, 2024.

Key Points: 
  • "We bring functional chocolate to Switzerland—a country famous for its chocolate—to reinvent the chocolate segment with added better-for-you value," asserts Dr. Shavon Jackson-Michel, Director of Medical & Scientific Affairs for DolCas Biotech.
  • To tackle this, DolCas partnered with a boutique chocolate maker to create the perfect chocolate with all the sensory experience consumers crave.
  • The collaboration resulted in an indulgent chocolate bite enriched with Curcugen's anti-inflammatory and antioxidant benefits to suit consumers desiring innovative delivery systems for wellness ingredients.
  • The 2x2-inch chocolate square is individually wrapped for visitors at Vitafoods Europe to sample the fun, tasty treat.

EQS-News: Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios

Retrieved on: 
星期五, 五月 3, 2024
Solubility, Partnership, Research, Drug development, API, Pharmaceutical industry

Korneuburg, Austria, 25 April 2024 – Marinomed Biotech AG (VSE:MARI) announces the establishment of an R&D collaboration under its Solv4U platform with Aché Laboratórios Farmaceuticos S.A., one of the largest and most innovative pharmaceutical companies in Brazil.

Key Points: 
  • Korneuburg, Austria, 25 April 2024 – Marinomed Biotech AG (VSE:MARI) announces the establishment of an R&D collaboration under its Solv4U platform with Aché Laboratórios Farmaceuticos S.A., one of the largest and most innovative pharmaceutical companies in Brazil.
  • Aché is known for its leadership in prescription medicines, and its commitment to developing innovative solutions for unmet medical needs.
  • Through its Solv4U partnership program, Marinomed offers its proprietary Marinosolv solubilization technology to customers from pharma and biotech to address solubility and bioavailability issues and support the formulation development of active pharmaceutical ingredients (APIs).
  • Cornelia Siegl, Head of Solv4U, commented: "We are excited to embark on this journey with Aché and look forward to the collaboration on this Solv4U project with such an innovative partner.

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

Retrieved on: 
星期四, 四月 25, 2024
Pain, FDA, Clobetasol, Inflammation, Phenylephrine, The central science, Solubility, Food, Research, State university system, Mydriasis, OD, Patient, Annual general meeting, Tropicamide, ARVO, Pharmaceutical industry

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products.

Key Points: 
  • NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products.
  • Eyenovia is planning to launch clobetasol later this summer, as a complement to Mydcombi, the company’s commercially available mydriasis agent.
  • “We look forward to incorporating this technology in future products, as well as launching clobetasol which uses APNT.
  • Clobetasol will be the first new ophthalmic steroid in many years, participating in a market estimated to be worth in excess of $1.3 billion annually.”

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Retrieved on: 
星期三, 四月 24, 2024
Mutation, Solubility, Safety, Pharmacokinetics, RAS, Half-life, MEK, NF1, BRAF, Patient, MAPK, RAF, Clinical trial, KTTA, SAN, Pharmaceutical industry

PAS-004 is being evaluated in a Phase 1 multicenter open label clinical trial ( NCT06299839 ) in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition.

Key Points: 
  • PAS-004 is being evaluated in a Phase 1 multicenter open label clinical trial ( NCT06299839 ) in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition.
  • “Completion of the initial dosing of the first cohort of 3 subjects is a significant milestone in Pasithea’s mission towards developing PAS-004 as a potential best-in-class next-generation MEK inhibitor.
  • PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials, with an expected extended half-life which may provide better compliance rates, as well as improved efficacy in NF1.
  • Macrocycles are known to exhibit stronger binding, better solubility and longer half-life with more selectivity and less off target effect as compared to acyclic small molecules.

Savanna Ingredients GmbH Appoints Palmer Holland as Exclusive Distribution Partner

Retrieved on: 
星期四, 四月 25, 2024
Psicose, Sucrose, Nutrition, Solubility, GMO, Partnership, Food industry, Metabolism, Cellobiose, Convenience food

CLEVELAND, April 24, 2024 /PRNewswire/ -- Savanna Ingredients GmbH and Palmer Holland, Inc. have signed an exclusive distribution partnership for crystalline Allulose and Cellobiose in the USA and Canada markets.

Key Points: 
  • CLEVELAND, April 24, 2024 /PRNewswire/ -- Savanna Ingredients GmbH and Palmer Holland, Inc. have signed an exclusive distribution partnership for crystalline Allulose and Cellobiose in the USA and Canada markets.
  • "Savanna Ingredients GmbH's value proposition and focus on quality and sustainability aligns well with Palmer Holland's mission to source high-quality natural ingredients designed to meet the needs of tomorrow," said Brendan Michel, Palmer Holland Business Manager - Health and Nutrition.
  • Allulose does not dock in the body, the calories are not metabolized but excreted," said Ralph Cartarius, Managing Director of Savanna Ingredients GmbH.
  • Another promising innovation from Savanna Ingredients GmbH is the functional carbohydrate Cellobiose.

InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance

Retrieved on: 
星期三, 四月 17, 2024
Simulations Plus, Pharmacopoeia, USP, TIM, Solubility, Doctor of Philosophy, United States Pharmacopeia, PBPK, ADMET, MBA, Excipient, Medical device

DELFT, Netherlands, April 17, 2024 /PRNewswire/ -- InnoGI Technologies (formerly The TIM Company) is pleased to announce an exciting, market-driven collaboration with Simulations Plus to combine its TIM Technology, part of the InnoGI SurroGUT™ platform, with the GastroPlus® and ADMET Predictor® modelling software offered by Simulations Plus.

Key Points: 
  • DELFT, Netherlands, April 17, 2024 /PRNewswire/ -- InnoGI Technologies (formerly The TIM Company) is pleased to announce an exciting, market-driven collaboration with Simulations Plus to combine its TIM Technology, part of the InnoGI SurroGUT™ platform, with the GastroPlus® and ADMET Predictor® modelling software offered by Simulations Plus.
  • Understanding drug behavior following oral administration is important because solubility and absorption profiles affect dosing and efficacy.
  • However, dynamic interactions between sparingly-soluble active pharmaceutical ingredients, excipients and the gastrointestinal (GI) environment are oversimplified in all static in vitro dissolution models and are very difficult to model using purely computational (in silico) approaches.
  • This will improve the predictive accuracy of physiologically-based pharmacokinetic (PBPK) models, physiologically-based biopharmaceutics models (PBBMs), and facilitate the development of mechanistic IVIVCs."